Contact Us   Having technical issues or questions regarding this product?
Please Contact Us.
BEI Resources currently limits the total number of "Made to Order" items which can be ordered by a registrant to 10 "Made to Order" items per 6 month period. Please check the Availability Status on the items you are ordering and limit orders appropriately.
NR-46422  Staphylococcus aureus, AID 1001123
Price: All BEI Resources products are provided
at no cost to registered researchers.
Organism: Staphylococcus aureus
Designations: AID 1001123
Biosafety Level: 2
Availability Status: In Stock
Store at: -60°C or colder
Contributor: B Limbago
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.

Staphylococcus aureus (S. aureus), strain AID 1001123 (also referred to as VRSA-11b and VRS11b) was isolated in 2010 in Delaware, USA from wound drainage of a 63-year-old female with a prosthetic joint infection who had been unsuccessfully treated with continuous vancomycin therapy for 3 months. AID 1001123 is a co-isolate with AIS 1001095 (VRS11a) from the same patient and they were isolated at the same time. Both are mecA positive but unlike AIS 1001095, AID 1001123 is phenotypically resistant to oxacillin by the cefoxitin disk diffusion test.

S. aureus, strain AID 1001123 is a vancomycin-resistant S. aureus (VRSA) strain. S. aureus, strain AID 1001123 was deposited as positive for mecA and vanA; negative for vanB, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AID 1001123 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AID 1001123 is constitutively resistant to vancomycin due to a mutation in vanR, which regulates the expression of the vanA operon. It has a second mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that the change in the type of peptidoglycans produced renders S. aureus, strain AID 1001123 susceptible to oxacillin. The complete genome sequence of S. aureus, strain AID 1001123 is available (GenBank: AHBV00000000).

Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 µg/mL vancomycin and 10% glycerol.
Citations: Acknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH: Staphylococcus aureus, Strain AID 1001123, NR-46422."
Additional Information: NARSA VRS11b
For a list of permits that may be required for shipping this product and to set the permit information preferences; please select a country from the drop down below.

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.

Click to read more
Return to Top

Notices and Disclaimers

BEI Resources products are intended for laboratory research purposes only. They are not intended for use in humans.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this site, BEI Resources makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. BEI Resources does not warrant that such information has been confirmed to be accurate.

Back to My Search